For phase 2 trials and monotherapy phase 3 enough data needs to exist for the FDA to make a determination to move onto a phase 3. There should be enough data for them to make that determination it just needs to be turned over. For HIV combo therapy Dr. Recknor and the new CRO will not know whether any necessary data is absent or impaired beyond use until the data is released.